News and Trends 13 May 2020
Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon
Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed. But, newer players, such as Novo Nordisk, are edging closer to the market. This year, it is predicted that NASH — the full name of […]